Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + MP0250
- Development stage
- Discontinued
- Lead developer
- Molecular Partners
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
pembrolizumab + MP0250 is a combination therapy investigated for the treatment of advanced solid tumors. It consists of pembrolizumab (Keytruda), a humanized monoclonal antibody that targets the Programmed Cell Death Protein 1 (PD-1) receptor to enhance anti-tumor immune responses, and MP0250, a multi-specific DARPin (Designed Ankyrin Repeat Protein) candidate developed by Molecular Partners AG. MP0250 is designed to simultaneously neutralize Vascular Endothelial Growth Factor (VEGF) and Hepatocyte Growth Factor (HGF), two key pathways involved in tumor angiogenesis and resistance to therapy. Additionally, MP0250 binds to human serum albumin (HSA) to extend its systemic half-life. The combination aims to provide synergistic anti-tumor activity by combining immune checkpoint blockade with the inhibition of multiple angiogenic and growth factor signaling pathways.
- Brand names
- Keytruda
- Other names
- pembrolizumabMP0250MP-0250MP 0250
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + MP0250.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + MP0250.